CHMP gives Eli Lilly diabetes drug the nod

Tirzepatide, a potential challenger of Novo Nordisk’s bestseller Ozempic, is now just a step away from European authorization for the treatment of type 2 diabetes.

Photo: Mike Blake/Reuters/Ritzau Scanpix

The European Medicines Agency’s (EMA) expert committee has given its positive recommendation for US-based Eli Lilly’s type 2 diabetes drug, tirzepatide, the company announced in a press release on Friday.

This almost sets the stage for competition with Danish pharmaceutical giant Novo Nordisk and its bestselling diabetes drug, Ozempic. The Committee for Medicinal Products for Human Use (CHMP) opinion paves for way for an official green light by the EU Commission, which has final say in matters of drug authorization.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs